胎球蛋白和糖脂代谢对代谢相关性脂肪性肝病的影响
Effects of Fetuin and Glycolipid Metabolism on Metabolic Associated Fatty Liver Disease
摘要: 代谢相关性脂肪性肝病(metabolic associated fatty liver disease, MAFLD)并非是一种静止的病变，会逐渐引起炎症细胞浸润、坏死、纤维化，甚至发展成为肝癌。胎球蛋白作为肝细胞因子，在人类代谢疾病、炎症等方面都具有重要作用。糖脂代谢异常可导致代谢相关性脂肪性肝病、糖尿病等代谢紊乱性疾病。近年有大量关于胎球蛋白A、胎球蛋白B、糖脂代谢与代谢相关性脂肪性肝病的研究。这篇综述将总结目前的研究进展，以便更好地了解胎球蛋白与糖脂代谢对代谢相关性脂肪性肝病的影响，为诊断、防治代谢相关性脂肪性肝病提供思路。
Abstract: Metabolic associated fatty liver disease (MAFLD) is not a static lesion, which can gradually lead to inflammatory cell infiltration, necrosis, fibrosis, and even development of liver cancer fetuin, as a hepatocyte factor, plays an important role in human metabolic diseases and inflammation. Abnor-mal glucose and lipid metabolism can lead to metabolic disorders such as metabolic associated fatty liver disease and diabetes. In recent years, there are a lot of studies on Fetuin A, Fetuin B, glucolipid metabolism and metabolic associated fatty liver disease. This review will summarize the current research progress, so as to better understand the effects of fetuin, and glucolipid metabolism on metabolic associated fatty liver disease, and provide ideas for the diagnosis, prevention and treat-ment of metabolic associated fatty liver disease.
文章引用：杨开霞, 施荣杰, 杨素莲, 陈怡, 张凤莲. 胎球蛋白和糖脂代谢对代谢相关性脂肪性肝病的影响[J]. 临床医学进展, 2022, 12(8): 7360-7366. https://doi.org/10.12677/ACM.2022.1281063

参考文献

[1] Meex, R.C.R. and Watt, M.J. (2017) Hepatokines: Linking Nonalcoholic Fatty Liver Disease and Insulin Resistance. Nature Reviews Endocrinology, 13, 509-520. [Google Scholar] [CrossRef] [PubMed]
[2] Sarin, S.K., Kumar, M., Eslam, M., et al. (2020) Liver Diseases in the Asia-Pacific Region: A Lancet Gastroenterology & Hepatology Commis-sion. The Lancet Gastroenterology & Hepatology, 5, 167-228. [Google Scholar] [CrossRef] 
[3] 夏明锋, 卞华, 高鑫. 从非酒精性脂肪肝到代谢相关性脂肪肝命名变化的思考[J/OL]. 中华糖尿病杂志, 2020, 12(7): 445-450. [Google Scholar] [CrossRef] 
[4] Eslam, M., Sarin, S.K., Wong, V.W.S., et al. (2020) The Asian Pacific Association for the Study of the Liver Clinical Practice Guidelines for the Diagnosis and Management of Metabolic Associated Fatty Liver Disease. Hepatology International, 14, 889-919. [Google Scholar] [CrossRef] [PubMed]
[5] Eslam, M., Sanyal, A.J., George, J., et al. (2020) MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology, 158, 1999-2014.e1. [Google Scholar] [CrossRef] [PubMed]
[6] 张成岗, 王雅娜. 研究脂肪肝患者的肝功能与血脂、血糖检测结果异常的关系[J/OL]. 世界最新医学信息文摘, 2019, 19(40): 158-159. [Google Scholar] [CrossRef] 
[7] 吴广忠, 苏建友. 肝功能血脂血糖联合检测在脂肪肝患者中的应用价值[J/OL]. 实用医技杂志, 2021, 28(7): 899-901. [Google Scholar] [CrossRef] 
[8] Lebreton, J.P., Joisel, F., Raoult, J.P., et al. (1979) Serum Concentration of Human Alpha 2 HS Glycoprotein during the Inflammatory Process: Evidence That Alpha 2 HS Glycoprotein Is a Negative Acute-Phase Reactant. Journal of Clinical Investigation, 64, 1118-1129. [Google Scholar] [CrossRef] 
[9] Sardana, O., Goyal, R. and Bedi, O. (2021) Molecular and Pathobiological Involvement of Fetuin-A in the Pathogenesis of NAFLD. Inflammopharmacology, 29, 1061-1074. [Google Scholar] [CrossRef] [PubMed]
[10] 张瑞, 刘东方. 胎球蛋白B对糖脂代谢影响的研究进展[J/OL]. 重庆医科大学学报, 2021, 46(9): 1031-1034. [Google Scholar] [CrossRef] 
[11] Cui, Z., Xuan, R. and Yang, Y. (2017) Serum Fetuin A Level Is Associated with Nonalcoholic Fatty Liver Disease in Chinese Population. Oncotarget, 8, 107149-107156. [Google Scholar] [CrossRef] [PubMed]
[12] 季红兵, 居会祥, 孙明忠, 等. 血清胎球蛋白A水平变化与代谢综合征的相关性[J]. 检验医学, 2017, 32(8): 677-681.
[13] 许方圆, 潘雨亭, 尚文斌. 胎球蛋白B在机体病理生理过程中的作用[J]. 生理科学进展, 2017, 48(4): 274-278.
[14] Dahlman, I., Eriksson, P., Kaaman, M., et al. (2004) 2-Heremans Schmid Glycoprotein Gene Polymorphisms Are Associated with Adipocyte Insulin Action. Diabetologia, 47, 1974-1979. [Google Scholar] [CrossRef] [PubMed]
[15] Haukeland, J.W., Dahl, T.B., Yndestad, A., et al. (2012) Fetuin A in Nonalcoholic Fatty Liver Disease: In Vivo and in Vitro Studies. European Journal of Endocrinology, 166, 503-510. [Google Scholar] [CrossRef] 
[16] Mukhopadhyay, S. and Bhattacharya, S. (2016) Plasma Fetuin-A Triggers Inflammatory Changes in Macrophages and Adipocytes by Acting as an Adaptor Protein between NEFA and TLR-4. Diabetologia, 59, 859-860. [Google Scholar] [CrossRef] [PubMed]
[17] Pal, D., Dasgupta, S., Kundu, R., et al. (2012) Fetuin-A Acts as an Endogenous Ligand of TLR4 to Promote Lipid-Induced Insulin Resistance. Nature Medicine, 18, 1279-1285. [Google Scholar] [CrossRef] [PubMed]
[18] Pan, X., Kaminga, A.C., Chen, J., et al. (2020) Fetuin-A and Fetuin-B in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis and Meta-Regression. International Journal of Environmental Re-search and Public Health, 17, 2735. [Google Scholar] [CrossRef] [PubMed]
[19] 汪玉倩, 徐可, 詹月萍, 等. 华蟾素对转化生长因子-β1诱导肝星状细胞激活的作用及机制研究[J/OL]. 中国临床药理学杂志, 2022, 38(13): 1452-1456. [Google Scholar] [CrossRef] 
[20] Sato, M., Kamada, Y., Takeda, Y., et al. (2015) Fetu-in-A Negatively Correlates with Liver and Vascular Fibrosis in Nonalcoholic Fatty Liver Disease Subjects. Liver Inter-national, 35, 925-935. [Google Scholar] [CrossRef] [PubMed]
[21] Meex, R.C., Hoy, A.J., Morris, A., et al. (2015) Fe-tuin B Is a Secreted Hepatocyte Factor Linking Steatosis to Impaired Glucose Metabolism. Cell Metabolism, 22, 1078-1089. [Google Scholar] [CrossRef] [PubMed]
[22] Momin, A.A., Bankar, M.P. and Bhoite, G.M. (2017) Association of Single Nucleotide Polymorphisms of Adiponectin Gene with Type 2 Diabetes Mellitus, and Their Influ-ence on Cardiovascular Risk Markers. Indian Journal of Clinical Biochemistry, 32, 53-60. [Google Scholar] [CrossRef] [PubMed]
[23] Pan, X., Wen, S.W., Bestman, P.L., et al. (2020) Fetuin-A in Metabolic Syndrome: A Systematic Review and Meta-Analysis. PLOS ONE, 15, e0229776. [Google Scholar] [CrossRef] [PubMed]
[24] Homeostasis of Glucose and Lipid in Non-Alcoholic Fatty Liver Disease.
https://www.corepubmed.com/Archive/Detail/30642126
[25] Han, H.S., Kang, G., Kim, J.S., et al. (2016) Regula-tion of Glucose Metabolism from a Liver-Centric Perspective. Experimental & Molecular Medicine, 48, e218. [Google Scholar] [CrossRef] [PubMed]
[26] Ding, H.R., Wang, J.L., Ren, H.Z., et al. (2018) Lipometabolism and Glycometabolism in Liver Diseases. BioMed Research International, 2018, Article ID: 1287127. [Google Scholar] [CrossRef] [PubMed]
[27] Chen, M., Liu, J., Yang, W., et al. (2017) Lipopolysaccharide Mediates Hepatic Stellate Cell Activation by Regulating Autophagy and Retinoic Acid Signaling. Autophagy, 13, 1813-1827. [Google Scholar] [CrossRef] [PubMed]
[28] Samuel, V.T., Liu, Z.X., Qu, X., et al. (2004) Mechanism of Hepatic Insulin Resistance in Non-Alcoholic Fatty Liver Disease. Journal of Biological Chemistry, 279, 32345-32353. [Google Scholar] [CrossRef] 
[29] Raddatz, K., Turner, N., Frangioudakis, G., et al. (2011) Time-Dependent Effects of Prkce Deletion on Glucose Homeostasis and Hepatic Lipid Metabolism on Dietary Lipid Oversupply in Mice. Diabetologia, 54, 1447-1456. [Google Scholar] [CrossRef] [PubMed]
[30] Samuel, V.T. and Shulman, G.I. (2016) The Pathogenesis of In-sulin Resistance: Integrating Signaling Pathways and Substrate Flux. Journal of Clinical Investigation, 126, 12-22. [Google Scholar] [CrossRef] 
[31] Satapathy, S. and Sanyal, A. (2015) Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease, 35, 221-235. [Google Scholar] [CrossRef] [PubMed]
[32] Nonalcoholic Fatty Liver Disease: A Systematic Review.
https://www.corepubmed.com/Archive/Detail/26057287
[33] Leptin Reverses Diabetes by Suppression of the Hypothalamic-Pituitary-Adrenal Axis.
https://www.corepubmed.com/Archive/Detail/24929951
[34] Lebensztejn, D.M., Flisiak-Jackiewicz, M., Białok-oz-Kalinowska, I., et al. (2016) Hepatokines and Non-Alcoholic Fatty Liver Disease. Acta Biochimica Polonica, 63, 459-467. [Google Scholar] [CrossRef] [PubMed]
[35] Li, Z., Lin, M., Liu, C., et al. (2018) Fetuin-B Links Non-alcoholic Fatty Liver Disease to Type 2 Diabetes via Inducing Insulin Resistance: Association and Path Analyses. Cyto-kine, 108, 145-150. [Google Scholar] [CrossRef] [PubMed]
[36] Shim, Y.S., Kang, M.J., Oh, Y.J., et al. (2017) Fetuin-A as an Alternative Marker for Insulin Resistance and Cardiovascular Risk in Prepubertal Children. Journal of Atherosclerosis and Thrombosis, 24, 1031-1038. [Google Scholar] [CrossRef] [PubMed]

为你推荐